Mydecine Innovations Group IncCanadian Securities Exchange:MYCOView on OTC Pink - Current Information
- LAST PRICE0.0100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0050/ 3,466
- Ask / Lots0.0100/ 514
- Open / Previous Close0.0100 / 0.0100
- Day Range
- 52 Week Range
- Volume81,030
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MYCO |
|---|---|---|
| 10:42 ET | 10000 | 0.01 |
| 10:44 ET | 60000 | 0.01 |
| 03:30 ET | 1000 | 0.01 |
| 03:33 ET | 10000 | 0.01 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mydecine Innovations Group Inc | 617.6K | 0.0x | --- |
WPD Pharmaceuticals Inc | 580.6K | -4.0x | --- |
EGF Theramed Health Corp | 577.7K | -2.3x | --- |
Chitogenx Inc | 832.3K | -0.2x | --- |
Lophos Holdings Inc | 859.6K | -0.7x | --- |
Albert Labs International Corp | 372.5K | -0.1x | --- |
Company Information
Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.
Contact Information
- Headquarters
- 1890-1075 West Georgia StreetVANCOUVER, BC, Canada V6E 3C9
- Phone
- 604-687-2038
- Fax
- 778-372-1790
Executives
- President, Chief Executive Officer, Director
- David Bartch
- Chief Financial Officer
- John Ross
- Chief Operating Officer
- Damon Michaels
- Chief Scientific Officer, Director
- Robert Roscow
- Chief Medical Officer
- Rakesh Jetly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $617.6K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.8M |
Mydecine Innovations Group Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.28 |
Book Value | $-0.23 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
